Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies

• Status: Recruiting
• Trial end date: 2023-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a Phase 1 trial to evaluate the safety, pharmacokinetics and efficacy of TG-1701, a Bruton's Tyrosine Kinase (BTK) inhibitor in patients with relapsed or refractory B-cell malignancies

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: TG Therapeutics, Inc.

Criteria

Inclusion Criteria:

• Relapsed or refractory histologically confirmed B-cell lymphoma or CLL

• Eastern Cooperative Oncology Group (ECOG) score of 0 to 2

• Adequate organ function

Exclusion Criteria:

• Prior therapy with a BTK inhibitor (ibrutinib, acalabrutinib, other)

• Any major surgery, chemotherapy or immunotherapy within the last 21 days

• Known hepatitis B virus, hepatitis C virus or HIV infection